Portal de Periódicos da CAPES

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

2021; Lippincott Williams & Wilkins; Volume: 39; Issue: 23 Linguagem: Inglês

10.1200/jco.21.00976

1527-7755

Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette, Amyé Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Della Makower, Margaret Block, Kimberly Morley, Chirag Jani, Craig Mescher, Shabana Jaynul Dewani, Bernard Tawfik, Lisa Flaum, Erica L. Mayer, William M. Sikov, Eve T. Rodler, Lynne I. Wagner, Angela DeMichele, Joseph A. Sparano, Antonio C. Wolff, Kathy D. Miller,

Cancer Genomics and Diagnostics

Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use of platinum agents in the TNBC basal subtype. The EA1131 trial hypothesized that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype TNBC treated with adjuvant platinum compared with capecitabine.